A Phase 4 interventional study of preservative free ZOLYMBUS™ 0.01%. in Eye Drops Self-instillation, Glaucoma and Dry Eye, sponsored by Southern College of Optometry. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Southern College of Optometry · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Glaucoma is a large group of intraocular pressure-sensitive conditions that can cause progressive retinal ganglion cell (RGC) damage/loss and ultimately results in visual field loss that can produce irreversible blindness. The literature suggests that about 3.5% of the world's population has glaucoma and that is expected to grow as life expectancy increases and individuals continue to live longer lives. The first line of defense against progressive glaucoma includes eye drops that lower intraocular pressure. Which unfortunately comes with side effects that can damage the ocular surface of the eye. Nearly 60% of those who use these persevered eye drops experience symptoms commonly associated with dry eye disease (DED). Such as burning, stinging and itching. Thus the purpose of this study is to determine the effectiveness of switching from a preserved topical glaucoma drop to a preservative free topical glaucoma drop in glaucoma patients who also have symptomatic dry eye disease.
Glaucoma is a large group of intraocular pressure-sensitive conditions that can cause progressive retinal ganglion cell (RGC) damage/loss and ultimately results in visual field loss that can produce irreversible blindness. The literature suggests that about 3.5% of the world's population has glaucoma and that is expected to grow as life expectancy increases and individuals continue to live longer lives. The first line of defense against progressive glaucoma includes eye drops that lower intraocular pressure. Which unfortunately comes with side effects that can damage the ocular surface of the eye. Nearly 60% of those who use these persevered eye drops experience symptoms commonly associated with dry eye disease (DED). Such as burning, stinging and itching. Thus the purpose of this study is to determine the effectiveness of switching from a preserved topical glaucoma drop to a preservative free topical glaucoma drop in glaucoma patients who also have symptomatic dry eye disease. This 3 month study aims to determine if patient comfort increases after switching to a preservative free eye drop.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
This study's planned enrollment of 40 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Browse Glaucoma studies →Southern College of Optometry is the lead sponsor of 18 studies on the registry; 10 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be given and instructed on how to use the product.
Drug: preservative free ZOLYMBUS™ 0.01%.
Participants will be given and instructed on how to use the preservative free eye drop and asked to report their ocular comfort.
Change in Eye Dryness (0-100 visual analog scale) scores at 3-month compared to baseline.
Participants will be asked to rate their eye dryness symptoms on a 0-100 scale with higher numbers indicating greater discomfort.
Time frame: Baseline to 3 months
Change in Eye Dryness (0-100 visual analog scale) scores at 1-month compared to baseline.
Participants will be asked to gauge their eye dryness on the VAS scale 0-100 with higher scores indicating more discomfort.
Time frame: baseline 1 month
No study locations are listed for this record.
Plan to share: Undecided — An abstract describing the study will be submitted to ARVO 2027. A manuscript on this same topic will be submitted to Contact Lens \& Anterior Eye (or similar journal) after submitting the conference abstract.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Feb 2027, 4 months later.
Of 32 non-industry phase 4 interventional studies under Glaucoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 4 months is below that.
Counting every sponsor, half of 44 studies reached it within 34 months; a quarter within 11 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Southern College of Optometry